Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.31 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3616377 | 1.00 | ANPEP (0.34) | ANPEPENPEPGPR88PSEN1PSEN2 | |
| SCHEMBL3616374 | 1.00 | ANPEP (0.34) | ANPEPENPEPGPR88PSEN1PSEN2 | |
| SCHEMBL2364187 | 1.00 | ANPEP (0.34) | ANPEPENPEPGPR88PSEN1PSEN2 | |
| SCHEMBL2364257 | 1.00 | ANPEP (0.34) | ANPEPENPEPGPR88PSEN1PSEN2 | |
| SCHEMBL2364185 | 1.00 | ANPEP (0.34) | ANPEPENPEPGPR88PSEN1PSEN2 | |
| SCHEMBL3616372 | 1.00 | ANPEP (0.34) | ANPEPENPEPGPR88PSEN1PSEN2 | |
| SCHEMBL3642072 | 0.96 | ANPEP (0.33) | ANPEPENPEPGPR88 | |
| SCHEMBL3336027 | 0.96 | ANPEP (0.33) | ANPEPENPEPGPR88 | |
| SCHEMBL3336032 | 0.96 | ANPEP (0.33) | ANPEPENPEPGPR88 | |
| SCHEMBL3600815 | 0.92 | ANPEP (0.33) | ANPEPENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081927-B1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-08-17 | — | — | EP | claimed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100190829-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC | 2010-07-29 | — | — | US | disclosed |
| US-20100160424-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | ANPEP 7/4885ENPEP 9/4885GPR88 4464/4885 |
| US-20100190829-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | ANPEP 20/4885ENPEP 17/4885GPR88 2963/4885 |
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | ANPEP 13/4885ENPEP 18/4885GPR88 2539/4885 |
| US-20100160424-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | ANPEP 20/4885ENPEP 17/4885GPR88 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.